Some preclinical data lends weight to this hypothesis; physostigmine (blood-brain barrier permeable cholinesterase inhibitor) treatment improved survival after experimental endotoxemia [8]. The gene discussed is BCHE; the disease is serum lipopolysaccharide activity.